Pancreatic Cancer

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.

Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.

A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.

An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.

Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.

Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Results from the CANFOUR trial of combining nadunolimab with chemotherapy appear to prolong overall survival among those with advanced or metastatic PDAC.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.

Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.

Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.

Adding metastasis-free directed radiation to chemotherapy more than tripled progression-free survival vs chemotherapy alone in the EXTEND trial.

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

The overall survival benefit seen with DOC1021 in a phase 1 trial of glioblastoma support the fast track status decision for the agent.

More than half of the patients who received mitazalimab plus chemotherapy experienced an unconfirmed objective response in the phase 2 OPTIMIZE-1 study.

Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.

Data from a phase 1 trial may support the utility of IBI343 for patients with advanced pancreatic ductal adenocarcinoma.